ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

NRSN NeuroSense Therapeutics Ltd

0.9988
-0.0212 (-2.08%)
2024年6月15日 - 終了
15分遅延
名称 銘柄コード 市場 種別
NeuroSense Therapeutics Ltd NRSN NASDAQ 普通株式
  前日比 前日比 % 現在値 時刻
-0.0212 -2.08% 0.9988 13:00:07
始値 安値 高値 終値 前日終値
1.04 0.9524 1.04 0.97 1.02
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/5/2022:00PRNUSNeuroSense Vice President of R&D Shiran Zimri, Ph.D. to..
2024/5/1422:05PRNUSNeuroSense Partners with PhaseV to Optimize Upcoming ALS..
2024/5/0721:45PRNUSNeuroSense Announces New Positive Data Analysis from..
2024/5/0222:19PRNUSNeuroSense Announces First Quarter 2024 Business Update
2024/4/2221:30PRNUSNeuroSense and Genetika+ Initiate Precision Medicine..
2024/4/1821:30PRNUSNeuroSense Presents Positive Data Validating Phase 2b..
2024/4/1221:30PRNUSNeuroSense to Present PARADIGM Data at the American Academy..
2024/4/1108:16PRNUSNeuroSense Announces Pricing of $4.5 Million Registered..
2024/4/0921:30PRNUSNeuroSense Collaborates with Lonza to Identify Exosome-based..
2024/4/0522:29PRNUSNeuroSense Announces Year End 2023 Financial Results and..
2024/2/2222:25EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/2/2122:30PRNUSNeuroSense Reports Additional Positive Results from its ALS..
2024/2/1403:20EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2024/2/1400:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2024/2/0723:38EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/2/0723:27PRNUSNeuroSense Regains Compliance with NASDAQ Minimum Bid Price..
2024/1/0922:49EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/1/0922:48EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/1/0922:45PRNUSNeuroSense Recaps Positive 2023 Achievements Including..
2023/12/2807:03EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
2023/12/2807:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/12/2807:00PRNUSNeuroSense Announces Receipt of Nasdaq Notice Regarding..
2023/12/2122:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/12/1506:30EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
2023/12/1423:41EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/12/1423:24PRNUSNeuroSense Reports New Data: Statistically Significant..
2023/12/0605:15EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
2023/12/0605:00EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
2023/12/0522:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/12/0522:00PRNUSNeuroSense's Phase 2b ALS Trial Achieves Primary Safety and..
2023/12/0514:15EDGAR2Form EFFECT - Notice of Effectiveness
2023/12/0506:01PRNUSNeuroSense to Report Phase 2b ALS Topline Primary Safety and..
2023/12/0420:17EDGAR2Form POS AM - Post-Effective amendments for registration..
2023/11/2823:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/11/2822:45PRNUSNeuroSense Announces Third Quarter 2023 Financial Results..
2023/11/2200:36EDGAR2Form POS AM - Post-Effective amendments for registration..
2023/11/1323:28EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/11/1323:20PRNUSNeuroSense Receives U.S. FDA Confirmation of CMC Strategy..
2023/11/0923:00PRNUSNeuroSense Therapeutics to Present at Upcoming U.S. and..
2023/11/0622:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/11/0622:30PRNUSNeuroSense Completes Dosing of Last Patient in the..
2023/11/0122:00PRNUSNeuroSense Therapeutics to Participate in BIO-Europe Fall
2023/10/1721:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/10/1721:30PRNUSNeuroSense CEO Provides Q3 2023 Update
2023/10/0422:12EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/10/0422:10PRNUSNeuroSense's PrimeC Demonstrates Outstanding Effect on ALS..
2023/10/0300:39EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/9/2022:16EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/9/2022:05PRNUSEuropean Medicines Agency Grants NeuroSense SME Status
2023/9/1922:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..

最近閲覧した銘柄

Delayed Upgrade Clock